Avaliação da adesão entre mulheres com câncer de mama em uso de quimioterápico adjuvante oral

• Ano de defesa: 2013
• Autor(a) principal: Freitas, Anderson Leite
• Orientador(a): Silva, Wellington Barros da
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Programa de Pós-Graduação: Pós-Graduação em Ciências Farmacêuticas
• Palavras-chave em Português: Farmacologia; Mamas - Câncer; Quimioterapia
• Palavras-chave em Inglês: Breast; Chemotherapy; Pharmacology
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: https://ri.ufs.br/handle/riufs/3928

Breast cancer is cancer that affects more women worldwide. Brazil has faced the similar rates of developed countries such as Japan. Estimates of INCA grow every year, in Sergipe for 2012 were provided 370 new cases. More than half of the drugs approved by the FDA are for oral use, which is preferred by more than 80% of patients receiving chemotherapy for various reasons. Studies have shown adherence ranging from 15-90%, this leads to not guarantee the effectiveness of treatment and increases the likelihood of cancer recurrence. Thus the present study aimed to assess adherence to chemotherapy among women diagnosed with breast cancer. Methodology: The methodological approach was divided into three stages: 1) Step exploratory or approach to the problem of the research, which was conducted a systematic review of the literature (RS) in order to check the different methodologies used to measure adherence to pharmacotherapy in cancer. Active search was performed in Medline / Pubmed, Scopus and Cinhal and Lilacs, Articles that measured adherence to pharmacotherapy in patients with oral cancer, 2) Stage of development of the measuring instrument, by means of the simplified translation and cross-cultural adaptation of the questionnaire "Cancer Patient Self-Report Questionnaire Non-Adherence" (CPSRNA) and the Morisky-Green questionnaire used to measure adherence to cancer treatment. The methodology was done with the translation, back-translation and pilot testing with 30 patients diagnosed with breast cancer, and 3) Stage field, where CPSRNA questionnaire was applied to a sample of patients diagnosed with breast cancer treatment at the Oncology Center Hospital Emergency Sergipe (HUSE). Results: In the development of RS 1089 citations were found, and after the screening process, 21 articles were included for review. Only seven articles used two or more methods. The methodology used was found in the MEMS seven articles and MPR in six articles, as sole measure to assess adherence. In the stage of development of the measuring instrument, the pilot test, it was observed that patients who considered quitting all his treatment had a score of 4.6 (± 0.5), this value was higher than those who did not consider stop treatment (score 2.6 ± 2.3). This difference was significant (ANOVA followed by the Mann- Whitney test = 7.48, p = 0.006). Similarly, the difference between the means of individuals who considered quitting part of treatment (mean score of 3.85 ± 1.77) than those who did not bother to stop their treatment (mean score of 2.65 ± 2.4), was also considered significant suggesting that those individuals have a higher probability of non-adherence to treatment. In the last article found a compliance rate of 31.85% for Morisky-Green questionnaire and family history was found in 49.1% of patients.